Eagle Pharmaceuticals
EGRX
$4.81
Share price
5.25%
Change (1 day)
-83.51%
Change (1 year)
Categories
P/S ratio for Eagle Pharmaceuticals (EGRX)
P/S ratio as of May 2024 (TTM): 0.2299
According to Eagle Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.229931. At the end of 2023 the company had a P/S ratio of 0.9881.
P/S ratio history for Eagle Pharmaceuticals from 2014 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 0.9881 | -17.77% |
| 2022 | 1.20 | -68.65% |
| 2021 | 3.83 | 18.63% |
| 2020 | 3.23 | -22.71% |
| 2019 | 4.18 | 59.07% |
| 2018 | 2.63 | -21.96% |
| 2017 | 3.37 | -48.03% |
| 2016 | 6.48 | -69.05% |
| 2015 | 20.9 | 84.82% |
| 2014 | 11.3 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 3.99 | 1,634.55% | 🇺🇸 USA |
 Novartis NVS | 3.99 | 1,637.16% | 🇨🇭 Switzerland |
 Eli Lilly LLY | 20.3 | 8,719.47% | 🇺🇸 USA |
 Amgen AMGN | 5.70 | 2,378.52% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 1.95 | 749.98% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 2.30 | 899.68% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | 1.00 | 337.08% | 🇮🇱 Israel |